Agenda Day 1
26 NOVEMBER 2013
12.00
Registration and Networking Refreshments
14:00 – 14:20
Chairperson’s welcome and opening remarks
Chair: Professor Trevor Jones CBE, Director Allergan & President of Sigma Tau Pharmaceuticals and member of the Pharma Steering Committee.
14:20 – 14:50
Keynote Address
Identifying and Defending Critical Assets: Is Pharma Different from Other Industries?
Are you sure your company hasn’t outsourced its crown jewels to third parties?
Do you really understand the complex interrelationships between power and dependence in outsourcing?
Do supply contracts deliver what the sponsor wants or what the contractor is willing to give?
Presented by: Andrew Cox – Chairman, International Institute for Advanced Purchasing & Supply (IIAPS)
14:50 – 15:10
Keynote Address
Exclusive overview of 2013 UK Life Sciences Start-up Environment: The Fourth Annual Review of Life Sciences Start-up Companies
Dr. Crocker’s presentation will look at some of the broader global trends over the last 12 months, supported by evidence of what’s going on in the UK, as well as long term trends in the creation and development of the next generation of European life science companies.
Presented by: Dr. Glenn Crocker – CEO of BioCity Group
15:10 – 15:45
Networking Refreshment Break
15:45 – 16:45
Panel Discussion:
Building a Resilient Supply Chain
The five strategic objectives in supply chain management are frequently defined by the 5Rs: Reliability, Responsiveness, Relationships, Resilience and Reach. While Pharma companies have striven in recent years to improve cost performance and optimise inventories, what price has been paid in terms of Reliability?
What Reliability issues have companies faced?
Why have Reliability issues occurred?
How can companies make their supply chains more Resilient?
What economic choices and trade-offs need to be made to achieve greater Resilience?
Panellists include: Dr Peter Comes, Corporate Vice President End-to-End Supply Network Strategy, Boehringer Ingelheim; Dr Sven Remmerbach, Director Business Development & Contract Manufacturing, Baxter; David Traynor, Vice President Manufacturing & Pharmaceutical Science, ProStrakan, Adrian Peskett, Director, Clinical Supply Logistics, Pfizer and Jonathan Blamey, Vice President Global Product & Account Leader, Global Life Sciences & Healthcare, DHL Supply Chain
Facilitated by: Julian Amey, Principal Fellow, Warwick Manufacturing Group, Warwick University and member of the Pharma Steering Committee.
16:45 – 17:45
Panel Discussion:
The Increasing Role of Collaboration – the Key to Success in the Pharma Industry?
What are the drivers for collaboration in the Pharma Industry and will they increase?
Fruitful areas for collaboration and why?
Collaboration Models
Success stories
Key factors for success
New Models
Barriers to success
Panellists include: David Roblin, Chief Medical Officer, Creabilis Biotech & Bio-Industry Advisor, NOCRI; Ian Muir, President Modified Release Technologies, Catalent Pharma Solutions; Alex Robertson, Director Sourcing R&D Pharmaceutical Development, AstraZeneca; Clive Badman, Vice President Investigational Materials Supply, GlaxoSmithKline; Alastair Florence, Director, EPSRC Centre for Innovative Manufacturing in Continuous Manufacturing and Crystallisation, Strathclyde Institute of Pharmacy and Biomedical Sciences
Facilitated by: Professor Trevor Jones CBE, Director Allergan & President of Sigma Tau Pharmaceuticals and member of the Pharma Steering Committee.
17:45 – 19:30
Champagne and canapé reception
Agenda Day 2
27 NOVEMBER 2013
08:30 – 08:55
Coffee & Pastries
09:00 – 10:00
Why aren’t we strategically transforming Pharma business relationships? An SME perspective
Are we moving to strategic partnerships? Who are the partners of choice? Are new relationships challenging the traditional business models?
Facilitated by: Jo Pisani, Partner Pharmaceuticals and Lifesciences Strategy, PricewaterhouseCoopers. Panellists include: John Wise, Executive Director, Pistoia Alliance, Tony Jones, Director of Business Development, One Nucleus, Martino Picardo, CEO, Stevenage Bioscience Catalyst and Thilo Jaeckel, Head of Contract Manufacturing Europe, F. Hoffmann La Roche
09:00 – 10:00
Exploring the ‘tougher’ side of integration – what part should regulators and patients play?
This session will bring together key stakeholders in patient advocacy, NHS, government, regulators and industry innovators to explore the issues and opportunities in creating a fully integrated healthcare system of world class proportions.
Facilitated by: Hedley Rees, Managing Director Biotech PharmaFlow & Global Advisory Board Member, Marken. Panellists include: James Christie, Head of Manufacturing, Oxford BioMedica, Bethan Bishop, Head of Innovation & Industry Engagement, Heart of England NHS Foundation Trust, Ramaswami Ramanan, Clinician/Cardiac Surgeon & Assessor and Judge, Innovation Den, Technology Strategy Board, Drew Hope, Head of Advanced Therapy Quality, ATMP GMP Unit, NIHR Biomedical Research Centre, Guy’s and St Thomas’ NHS Foundation Trust & King’s College London and Nick Rich, Professor of Operations Management & Head HRM, School of Management, Swansea University
10:05 – 11:05
Risk sharing in pharmaceutical development
R&D productivity within Big Pharma continues to decline small and start-up companies have now become the main source of innovation. However, all too often in Europe they face a critical funding gap pre proof of concept. CDMOs and CROs can help alleviate this by offering services on a risk reward basis or can take equity stakes in companies – however many CDMOs and CROs lack the R&D knowledge to make the right portfolio decisions. Is this a sustainable model? What new capabilities and skills will be needed on both sides and what can they learn from established Pharma companies related to this?
Facilitated by: Mark Cassidy, President API Services, Piramal Healthcare. Panellists include: Denis Croisat, Director Lead Generation – CMC, Biologics Sourcing & External Business Opportunities, Sanofi, Richard Beesley, IDD/IDDC EMEA Business Manager, 3M, Dianne Sharp, Managing Director, SCM Pharma, Murali Dhar, Senior Director Operations & Strategic Planning, Proprietary Products, Dr Reddy’s, Sunil Shah, Director, O2h Ventures and Julien Meissonnier, R&D Platform Director, Catalent Pharma Solutions.
10:05 – 11:05
Increasing Pricing Pressure: Partnerships & Strategies to Compete
How to compete with the increasing pressure from payers for lower price drugs
Lowest cost vs niche
Shifting your product portfolio to a different payer and moving to different categories of products
Facilitated by: Ewan Livesey, Senior Vice President Corporate Development, Lupin. Panellists include: Guy Clark, Chief Strategy Officer, Amdipharm Mercury Company, Douglas Andrews, Chief Executive Officer, Stravencon, Neil Johnson, Director, RJW & Partners & Richard Learwood, Global Director Brand Strategy & Innovation, PGT Healthcare.
11:05 – 11:35
Networking Coffee Break
11:35 – 12:35
Investing in innovation to make a return – organising the value chain to deliver a return on shareholder capital?
This session will cover the challenge of funding innovation and remaining relevant to the suppliers of capital.
The failure of innovation in the pharmaceutical industry is having a dramatic impact on the shape of R&D, the desire to outsource and the flight of capital away from venture firms – the traditional source of external opportunity. In this session we discuss the challenges that are faced by all players in the value chain in making good on our promise to patients and shareholders.
Facilitated by: Rowan Gardner, Chair BioLauncher & European Advisory Board Member, Astia. Panellists include: Alan Lamont, Executive Director Global External Research & Development, Eli Lilly, Chris Hollowood, Partner, Syncona Partners, Richard Seabrook, Head of Business Development, Technology Transfer, The Wellcome Trust and Marco Sardina, Research & Development Director, Zambon Pharma.
11:35 – 12:35
Beyond Account Management – Leveraging Pharma supply-base capabilities to co-create value in the broader Healthcare sector
- Pharma business imperatives and opportunities
- Identifying the unique capabilities in supplier community
- Merging KAM and SRM approaches to drive greater value
The intent of the session is to link the supply base through to the ultimate customer through identification and fulfilment of unmet needs through the entire value chain.
Speakers include: Sammy Rashed, Co-Founder, The Beyond Group & Former Global Head of Productivity and Sourcing Strategy, Novartis Pharmaceuticals, Detlef Behrens, Vice President Business Development Formulations, Piramal Healthcare, Thilo Jaeckel, Head of Contract Manufacturing Europe, F. Hoffmann La Roche & Giles Breault, Co-Founder, The Beyond Group & Former Chief Procurement Officer, Novartis Pharmaceuticals.
12:35 – 13:35
Networking Luncheon
13:35 – 14:35
Do big Pharma need to re-address their key competencies?
Big Pharma is always discussing the needs of ‘make versus buy’ during the development of medicines. Does big Pharma however, have the right people with the right skills to ‘make’ never mind buy!
Has the continuous wave of mergers, acquisitions, downsizing and re-organisation over the last 7 years produced organisations with insufficient experience or skills to develop products?
This session will discuss at all levels within big Pharma whether there are competent scientists and professionals at the helm.
Facilitated by: Professor Luigi Martini, Chair in Pharmaceutical Innovation, King’s College London. Panellists include: Patrick Crowley, Visiting Professor School of Pharmacy, Kings College University of London, Steve Wicks, Professor of Pharmaceutical Science, University of Greenwich, Kurt Hertogs, Head Platform Innovation & Incubator Strategy, Johnson & Johnson and Alex Robertson, Director Sourcing R&D Pharmaceutical Development, AstraZeneca.
13:35 – 14:35
Globalisation vs. Market Entry Barriers
This panel session will focus on a topic that is seen as one of the major threats within the pharmaceutical industry; the trend to source Materials and API in Asia, increasing pressure on prices and financial pressure on healthcare systems. Alternatively we can observe that governments globally are restricting import and even closing borders for the importation of pharmaceutical products to foster local production. This topic can be observed globally and is not only restricted to emerging countries but can also be seen in mature markets. This trend normally is in contradiction to the trend of consolidation of products and global supply and leads mostly to higher cost of goods. Examples are to be found globally with countries like Argentina, Venezuela and Algeria, but also countries like Russia or Indonesia. This session will tackle these global trends and the complex challenges they present head on.
Facilitated by: Axel Sinner, Principal Pharma/Life Sciences, Camelot Management Consultants. Panellists include: Guy Clark, Chief Strategy Officer, Amdipharm Mercury Company, Murali Dhar, Senior Director Operations & Strategic Planning, Proprietary Products, Dr Reddy’s and Allan Jensen, Director Corporate Procurement & Contract Manufacturing, Xellia Pharmaceuticals
14:40 – 15:40
Biosimilars: Big pharma and generics treading on each other’s toes
As we near the first monoclonal antibody biosimilar approval in Europe, it seems that biosimilars (at least in Europe) will become a key enabler in reducing healthcare costs and will foster a new product category. Who is placed to win in a biosimilars world? For Big Pharma – biosimilars de-risk the portfolio and Big Pharma can leverage their key skills in marketing and managing risk. For Generic companies, biosimilars potentially offer higher margin products but not without some R&D risk and some unfamiliar capabilities. However the Rx/Gx interface is also blurring. This panel will discuss the key factors for success in a biosimilars world from the two perspectives.
Facilitated by: Jo Pisani, Partner Pharmaceuticals and Lifesciences Strategy, PricewaterhouseCoopers Panellists include: Fritjof Linz, Vice President Global R&D/PD, DSM Biologics, Axel Sinner, Principal Pharma/Life Sciences, Camelot Management Consultants, Douglas Andrews Chief Executive Officer, Stravencon, Alan Sheppard, Principal, Global Generics, Thought Leadership, IMS Health and Conrad Savoy, Senior Pharma/Biotech Advisor & Former Chief Executive Officer Biopartners.
14:40 – 15:40
East vs West: Future Trends in Partnering Discovery and CMC Activities
There is, however, a small but growing belief that the full costs of partnering in these regions, inclusive of increasing local salaries, in-house management costs, and other factors, as well as a changing business/regulatory environment may negate the cost advantage in the near future.
This panel discussion is to explore perceptions of future trend – whether to continue the partnering of activities in the east or the reverse, and for what activities.
Facilitated by: David Harrison, Director Manufacturing Alliances, UCB Pharma. Panellists include: Joaquin Santos Benito, Senior Director External Manufacturing EMEA, Janssen Pharmaceutica, Fabio Brischetto, Business Development Manager Manufacturing Operations, Zambon Pharma and Andreas Weiler, Global Head of Strategic Marketing, SAFC.
15:40 – 16:00
Networking Coffee Break
16:00 – 17:00
The Future of the Generics Industry
The traditional generics industry is coming under threat. As some Big Pharma foster established products businesses and build a generics presence in emerging markets, while Gx companies suffer from poor Big Pharma R&D productivity to supplying a pipeline, there are questions about the sustainability of a pure generics business. However, the volume of generics is increasing as healthcare economies strive to cut costs and the patent cliff continues. Is there room for a pure generics player in this new world and what will the new success factors be?
Facilitated by: Luigi Martini, Chair in Pharmaceutical Innovation, King’s College London. Panellists include: Chanelle McCoy, Director Medical Business, Chanelle Medical, Ewan Livesey, Senior Vice President Corporate Development, Lupin, Alan Sheppard, Principal, Global Generics, Thought Leadership, IMS Health and Kim Kjornas, Senior Director Sales & Marketing Rx/Gx Europe, Actavis.